Lower urinary tract symptoms after hormone replacement therapy in Japanese patients with late-onset hypogonadism: A preliminary report: Short Communication

International Journal of Urology

Volumn 16, Issue 2, 2009, Pages 212-214

  Takao, Tetsuya ^a   Tsujimura, Akira ^a   Nakayama, Jiro ^a   Matsuoka, Yasuhiro ^a   Miyagawa, Yasushi ^a   Takada, Shingo ^b   Nonomura, Norio ^a   Okuyama, Akihiko ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b OSAKA POLICE HOSPITAL   (Japan)

Author keywords

HRT; LOH; LUTS; Testosterone

Indexed keywords

CHORIONIC GONADOTROPIN; TESTOSTERONE ENANTATE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPARATIVE STUDY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; INTERNATIONAL PROSTATE SYMPTOM SCORE; JAPANESE; KING'S HEALTH QUESTIONNAIRE; MALE; PRIORITY JOURNAL; PROSTATE; QUALITY OF LIFE; QUESTIONNAIRE; RANK SUM TEST; SYMPTOM; TREATMENT DURATION; URINARY TRACT DISEASE;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; CHORIONIC GONADOTROPIN; HORMONE REPLACEMENT THERAPY; HUMANS; HYPOGONADISM; MALE; MIDDLE AGED; TESTOSTERONE; URINATION DISORDERS;

EID: 60349125972     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02202.x     Document Type: Article

References (30)

1. Morales A, Heaton JP, Carson CC 3rd. Andropause: A misnomer for a true clinical entity. J. Urol. 2000 163 : 705 12.
2. Comhaire FH. Andropause: Hormone replacement therapy in the ageing male. Eur. Urol. 2000 38 : 655 62.
3. Vermeulen A. Andropause. Maturitas 2000 34 : 5 15.
4. Morales A, Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male. Aging Male 2002 5 : 74 86.
5. Nieschlag E, Swerdloff R, Behre HM et al. Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations. Eur. Urol. 2005 48 : 1 4.
6. Namiki M, Akaza H, Shimazui T et al. Clinical practice manual for late-onset hypogonadism syndrome. Int. J. Urol. 2008 15 : 377 88.
7. Hong BS, Ahn TY. Recent trends in the treatment of testosterone deficiency syndrome. Int. J. Urol. 2007 14 : 981 5.
8. Reid IR, Wattie DJ, Evans MC, Stapleton JP. Testosterone therapy in glucocorticoid-treated men. Arch. Intern. Med. 1996 156 : 1173 7.
9. Rabkin JG, Wagner GJ, Rabkin R. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism. J. Clin. Psychopharmacol. 1999 19 : 19 27.
10. Rabkin JG, Wagner GJ, Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry. 2000 57 : 141 7. discussion 55-6.
11. Seidman SN, Spatz E, Rizzo C, Roose SP. Testosterone replacement therapy for hypogonadal men with major depressive disorder: A randomized, placebo-controlled clinical trial. J. Clin. Psychiatry. 2001 62 : 406 12.
12. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J. Clin. Endocrinol. Metab. 2003 88 : 2673 81.
13. Wittert GA, Chapman IM, Haren MT, Mackintosh S, Coates P, Morley JE. Oral testosterone supplementation increases muscle and decreases fat mass in healthy elderly males with low-normal gonadal status. J. Gerontol. A. Biol. Sci. Med. Sci. 2003 58 : 618 25.
14. Amory JK, Watts NB, Easley KA et al. Exogenous testosterone or testosterone with finasteride increases bone mineral density in older men with low serum testosterone. J. Clin. Endocrinol. Metab. 2004 89 : 503 10.
15. Tsujimura A, Matsumiya K, Takao T et al. Treatment with human chorionic gonadotropin for PADAM: A preliminary report. Aging Male 2005 8 : 175 9.
16. Tsujimura A, Takada S, Matsuoka Y et al. Is discontinuation of hormone replacement therapy possible for patients with late-onset hypogonadism? Int. J. Urol. 2008 15 : 625 9.
17. Tenover JS. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 1992 75 : 1092 8.
18. Munzer T, Harman SM, Hees P et al. Effects of GH and/or sex steroid administration on abdominal subcutaneous and visceral fat in healthy aged women and men. J. Clin. Endocrinol. Metab. 2001 86 : 3604 10.
19. Morales A. Androgen replacement therapy and prostate safety. Eur. Urol. 2002 41 : 113 20.
20. Gould DC, Kirby RS. Testosterone replacement therapy for late onset hypogonadism: What is the risk of inducing prostate cancer? Prostate Cancer Prostatic. Dis. 2006 9 : 14 18.
21. Takao T, Tsujimura A. Prostate stem cells: The niche and cell markers. Int. J. Urol. 2008 15 : 289 94.
22. Isaacs JT. Antagonistic effect of androgen on prostatic cell death. Prostate 1984 5 : 545 57.
23. Maggi CA, Manzini S, Giuliani S, Meli A. Infravesical outflow obstruction in rats: A comparison of two models. Gen. Pharmacol. 1989 20 : 345 9.
24. Pandita RK, Persson K, Hedlund P, Andersson KE. Testosterone-induced prostatic growth in the rat causes bladder overactivity unrelated to detrusor hypertrophy. Prostate 1998 35 : 102 8.
25. Tatemichi S, Akiyama K, Kobayashi M, Yamazaki Y, Yokoyama O, Uruno T. A selective alpha1A-adrenoceptor antagonist inhibits detrusor overactivity in a rat model of benign prostatic hyperplasia. J. Urol. 2006 176 : 1236 41.
26. Lunenfeld B, Nieschlag E. Testosterone therapy in the aging male. Aging Male 2007 10 : 139 53.
27. Holmang S, Marin P, Lindstedt G, Hedelin H. Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men. Prostate. 1993 23 : 99 106.
28. Gooren LJ. A ten-year safety study of the oral androgen testosterone undecanoate. J. Androl. 1994 15 : 212 15.
29. Marks LS, Mazer NA, Mostaghel E et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: A randomized controlled trial. JAMA 2006 296 : 2351 61.
30. Behre HM, Bohmeyer J, Nieschlag E. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin. Endocrinol. (Oxf) 1994 40 : 341 9.